Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia

BACKGROUND: Patients with relapsed/refractory (R/R) Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) have a poor prognosis and limited treatment options. METHODS: The efficacy of inotuzumab ozogamicin (InO), a humanized anti‐CD22 monoclonal antibody conjugated to the cytotox...

Descripción completa

Detalles Bibliográficos
Autores principales: Stock, Wendy, Martinelli, Giovanni, Stelljes, Matthias, DeAngelo, Daniel J., Gökbuget, Nicola, Advani, Anjali S., O’Brien, Susan, Liedtke, Michaela, Merchant, Akil A., Cassaday, Ryan D., Wang, Tao, Zhang, Hui, Vandendries, Erik, Jabbour, Elias, Marks, David I., Kantarjian, Hagop M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983935/
https://www.ncbi.nlm.nih.gov/pubmed/33231879
http://dx.doi.org/10.1002/cncr.33321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983935/
https://www.ncbi.nlm.nih.gov/pubmed/33231879
http://dx.doi.org/10.1002/cncr.33321

Ejemplares similares